ANZCTR search results

The effects of an acute curcumin supplementation on team sport athletes performance and recovery. The study involves team sport athletes, aged 18-35. This is a randiomised, double-blinded, cross-over study where participants will consume either a curcumin supplement or a placebo at a time, without knowing which one they were given. They will be tested on their athletic performance and recovery over five sessions, with a break between the supplements to ensure any effects of the supplements have worn off. The study will measure performance through a battery of field tests and recovery through blood sample collection and questionnaires. The hypothesis of this study an acute dose of curcumin supplementation will reduce the detriment in exercise performance post-fatiguing exercise. Additionally, muscle damage markers and inflammation will be reduced, and the participants’ perceived recovery will be improved.

The aims of this study are: 1. To determine the feasibility (acceptability and fidelity) of implementing the physiotherapy guideline in patients with pneumonia, incorporating a set dosage of ventilator hyperinflation (VHI) treatment, with target volume determined for each patient according to their estimated inspiratory reserve volume, based on height as per Jacob et al (2021). 2. To explore pneumonia phenotypes which demonstrate treatable traits that are amenable to respiratory physiotherapy intervention commenced during the acute period of invasive mechanical ventilation. 3. To determine the effect of a course of VHI treatment method], at a set dosage and frequency of three times daily for the duration of the period that patients are on the mechanical ventilator on symptomatology and patient-centred outcomes. 4. To determine the cost-effectiveness of physiotherapy guideline care incorporating a course of new VHI treatment for pneumonia requiring invasive ventilation in ICU. It is hypothesised that best practice physiotherapy guideline care, with incorporation of protocolised VHI treatment is safe, feasible and effective in improving patient-important outcomes for critically ill adults requiring invasive mechanical ventilation for pneumonia.

BHV-1300 is being developed by Biohaven Therapeutics Limited for the potential treatment of immune-mediated diseases. This is a single center, Phase 1, randomized, open-label, placebo controlled, multiple dose study in healthy adults. This study will include 1 multiple dose cohort to evaluate the safety and tolerability of BHV-1300 and to characterize the pharmacokinetic profile of BHV-1300.

The purpose of this study was to understand how accurately surgical ward round patient case notes are. This was achieved by comparing audio-visual recordings of the ward round, to patient case notes. The hypothesis of this study is that ward round case notes are accurate and capture what is discussed in the ward round.

The study is designed to identify patients from different hospital departments who have been admitted to the Transplant unit, the ICU and/or Outpatients Department, suspected of having a Blood Stream Infection (BSI) and/or an invasive fungal infection. Clinical assessment of patients eligible to be enrolled in this study will be conducted by the department physicians. Study subjects will have blood samples collected for blood culture (standard of care/SOC), as well as an additional blood EDTA tube, and/or bronchiolar lavage and/or sputum samples collected at the same time. These samples will be processed using the Microbio InfectID assay in an experienced diagnostic laboratory. Diagnostic accuracy will be calculated with respect to the SOC blood culture and other culture-based test results.

We are conducting a pilot study to see how well a cardiac rehabilitation program helps patients recover after open heart surgery. We will use the Duke Activity Status Index (DASI) tool to measure how much the program improves your ability to perform daily activities. This study aims to gather early information to understand how cardiac rehabilitation might help patients get better after their surgery. We are also interested in learning about the recovery of patients who choose not to participate in a cardiac rehabilitation program. This will help us compare the outcomes of those who do and do not participate in the rehabilitation program.

This is a randomised controlled trial to evaluate the acceptability, feasibility, and potential efficacy of a novel web-based electronic point-of-care tool, "e-HANDI," to facilitate GPs' prescription and patients' use of effective NDIs in primary care. e-HANDI is a web-based user-centred point-of-care tool that is systematically developed from the bottom-up to facilitate easier, practical prescribing of NDIs in primary care.

The aim of this study is to determine the Optimal Biological Dose, and Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of Actinium (225Ac) Ibu-DAB-PSMA for the Treatment of PSMA-positive Progressive Metastatic Castration Resistant Prostate Cancer Who is it for? You may be eligible for this study if you are a Male participant aged at least 18 years have a histologically, pathologically, and/or cytologically confirmed metastatic adenocarcinoma of the prostate without significant sarcomatoid or spindle or neuroendocrine or small cell differentiation components. Stage IV prostate cancer with at least one lesion that is measurable on baseline CT or MRI, or present on bone scan imaging, obtained within 30 days prior to trial enrolment. At least one PSMA PET/CT positive lesion (i.e., higher than liver uptake) within 30 days prior to enrolment. Study details Participants will receive different numbers of doses in cycles (two, three, or six), which will test 3 different dose levels/strengths of ITM-22. Participants will then be tested for optimal biological dose, tolerability and safety, preliminary efficacy signals of actinium, pharmacokinetics and biomarkers. It is hoped that findings from this study will demonstrate that actinium (225Ac) Ibu-DAB-PSMA is safe and well tolerated by patients with progressive mCRPC. The results in this study will determine the optimal biological dose for expansion of the trial in phase 2.

The research aims to develop and evaluate a delivery model for implementing StandingTall within community aged care services. The delivery model has been designed and will be refined in co-design with aged care providers. The primary outcome will assess adoption (health care professionals are referring clients to the intervention) to the program. Secondary outcome measures include reach, effectiveness, adoption (uptake), implementation, and maintenance.

This study aims to investigate the feasibility and acceptability of patient initiated follow-up (PIFU) following surgery for low risk endometrial cancer. Who is it for? You may be eligible for this study if you are a woman aged 18 years or over who has completed definitive primary surgical treatment for endometrial endometrioid adenocarcinoma, and has been assessed by a gynaecological oncology multidisciplinary team as having low risk disease in whom adjuvant therapy is not indicated. Study details Participants will be randomly allocated to PIFU, or standard of care follow up 6-monthly with the patient's General Practitioner. In the PIFU group, participants will receive an education session at baseline regarding when and how to contact the gynaecologic oncology service. Data will be collected on how many women on PIFU refer themselves back to the clinic. All participants will be followed up at 12 months post-baseline to conduct quality of life measures and cancer recurrence rates will be assessed. It is hoped that findings from this study inform a larger trial in future to assess healthcare costs and long term cancer outcomes associated with PIFU in endometrial cancer.